Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients

Journal of Trauma and Acute Care Surgery

Volumn 80, Issue 1, 2016, Pages 16-25

  Chapman, Michael P ^a,b   Moore, Ernest E ^a   Moore, Hunter B ^a   Gonzalez, Eduardo ^a   Gamboni, Fabia ^a   Chandler, James G ^a   Mitra, Sanchayita ^a   Ghasabyan, Arsen ^a   Chin, Theresa L ^a   Sauaia, Angela ^a   Banerjee, Anirban ^a   Silliman, Christopher C ^a,c,d  

^a DENVER HEALTH MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c CHILDREN S HOSPITAL   (United States)

^d Bonfils Blood Center   (United States)

Author keywords

APC; Hyperfibrinolysis; Massive transfusion; PAI 1; TPA; Trauma

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; COMPLEX FORMATION; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HUMAN; HYPERFIBRINOLYSIS; INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN SECRETION; BLOOD; BLOOD CLOTTING DISORDER; CASE CONTROL STUDY; INJURY SCALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; THROMBOELASTOGRAPHY;

ADULT; BLOOD COAGULATION DISORDERS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HUMANS; INJURY SEVERITY SCORE; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBELASTOGRAPHY; TISSUE PLASMINOGEN ACTIVATOR; WOUNDS AND INJURIES;

EID: 84952717613     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0000000000000885     Document Type: Conference Paper

References (53)

1. Armand R, Hess JR. Treating coagulopathy in trauma patients. Transfus Med Rev. 2003;17(3):223-231.
2. Blackbourne LH, Baer DG, Cestero RF, Inaba K, Rasmussen TE. Exsanguination shock: the next frontier in prevention of battlefield mortality. J Trauma. 2011;71(1 Suppl):S1-S3.
3. Ganter MT, Pittet JF. New insights into acute coagulopathy in trauma patients. Best Pract Res Clin Anaesthesiol. 2010;24(1):15-25.
4. Gonzalez EA, Moore FA, Holcomb JB, Miller CC, Kozar RA, Todd SR, Cocanour CS, Balldin BC, McKinley BA. Fresh frozen plasma should be given earlier to patients requiring massive transfusion. J Trauma. 2007; 62(1):112-119.
5. Kashuk JL, Moore EE, Johnson JL, Haenel J, Wilson M, Moore JB, Cothren CC, Biffl WL, Banerjee A, Sauaia A. Postinjury life threatening coagulopathy: is 1:1 fresh frozen plasma:packed red blood cells the answer? J Trauma. 2008;65(2):261-270.
6. Kashuk JL, Moore EE, Sawyer M, Le T, Johnson J, Biffl WL, Cothren CC, Barnett C, Stahel P, Sillman CC, et al. Postinjury coagulopathy management: goal directed resuscitation via POC thrombelastography. Ann Surg. 2010;251(4):604-614.
7. Chapman MP, Moore EE, Ramos CR, Ghasabyan A, Harr JN, Chin TL, Stringham JR, Sauaia A, Silliman CC, Banerjee A. Fibrinolysis greater than 3%is the critical value for initiation of antifibrinolytic therapy. J Trauma Acute Care Surg. 2013;75(6):961-967.
8. Cotton BA, Harvin JA, Kostousouv V, Minei KM, Radwan ZA, Schöchl H, Wade CE, Holcomb JB, Matijevic N. Hyperfibrinolysis at admission is an uncommon but highly lethal event associated with shock and prehospital fluid administration. J Trauma Acute Care Surg. 2012;73(2):365-370.
9. Chin TL, Moore EE, Moore HB, Gonzalez E, Chapman MP, Stringham JR, Ramos CR, Banerjee A, Sauaia A. A principal component analysis of postinjury viscoelastic assays: clotting factor depletion versus fibrinolysis. Surgery. 2014;156(3):570-577.
10. Gando S, Tedo I, Kubota M. Posttrauma coagulation and fibrinolysis. Crit Care Med. 1992;20(5):594-600.
11. Kutcher ME, Cripps MW, McCreery RC, Crane IM, Greenberg MD, Cachola LM, Redick BJ, Nelson MF, Cohen MJ. Criteria for empiric treatment of hyperfibrinolysis after trauma. J Trauma Acute Care Surg. 2012;73(1):87-93.
12. CRASH-2 collaborators, Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011; 377(9771):1096-1101, 101.e1-101.e2.
13. CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23-32.
14. Moore HB, Moore EE, Gonzalez E, Hansen KC, Dzieciatkowska M, Chapman MP, West B, Banerjee A, Silliman CC. Hemolysis exacerbates hyperfibrinolysis, whereas platelolysis shuts down fibrinolysis: evolving concepts of the spectrum of fibrinolysis in response to severe injury. Shock. 2015;43(1):39-46.
15. Urano T, Wu K, Ihara H, Takada Y, Takada A. Novel mechanism to enhance tPA-induced fibrinolysis: effect of limited proteolysis of PAI-1 by neutrophil elastase. Pol J Pharmacol. 1996;48(2):209-213.
16. Wu K, Urano T, Ihara H, Takada Y, Fujie M, Shikimori M, Hashimoto K, Takada A. The cleavage and inactivation of plasminogen activator inhibitor type 1 by neutrophil elastase: the evaluation of its physiologic relevance in fibrinolysis. Blood. 1995;86(3):1056-1061.
17. Valle EJ, Allen CJ, Van Haren RM, Jouria JM, Li H, Livingstone AS, Namias N, Schulman CI, Proctor KG. Do all trauma patients benefit from tranexamic acid? J Trauma Acute Care Surg. 2014;76(6):1373-1378.
18. Cole E, Davenport R, Willett K, Brohi K. Tranexamic acid use in severely injured civilian patients and the effects on outcomes: a prospective cohort study. Ann Surg. 2015;261(2):390-394.
19. Harvin JA, Peirce CA, Mims MM, Hudson JA, Podbielski JM, Wade CE, Holcomb JB, Cotton BA. The impact of tranexamic acid on mortality in injured patients with hyperfibrinolysis. J Trauma Acute Care Surg. 2015; 78(5):905-909.
20. Schöchl H, Cadamuro J, Seidl S, Franz A, Solomon C, Schlimp CJ, Ziegler B. Hyperfibrinolysis is common in out-of-hospital cardiac arrest: results from a prospective observational thromboelastometry study. Resuscitation. 2013;84(4):454-459.
21. Brohi K, Cohen MJ, Davenport RA. Acute coagulopathy of trauma: mechanism, identification and effect. Curr Opin Crit Care. 2007;13(6): 680-685.
22. Brohi K, Cohen MJ, Ganter MT, Schultz MJ, Levi M, Mackersie RC, Pittet JF. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma. 2008;64(5):1211-1217.
23. Morton AP, Moore EE, Wohlauer MV, Lo K, Silliman CC, Burlew CC, Banerjee A. Revisiting early postinjury mortality: are they bleeding because they are dying or dying because they are bleeding? J Surg Res. 2013;179(1):5-9.
24. Björquist P, Brohlin M, Ehnebom J, Ericsson M, Kristiansen C, Pohl G, Deinum J. Plasminogen activator inhibitor type-1 interacts exclusively with the proteinase domain of tissue plasminogen activator. Biochim Biophys Acta. 1994;1209(2):191-202.
25. Strömqvist M, Karlsson KE, Björquist P, Andersson JO, Byström M, Hansson L, Johansson T, Deinum J. Characterisation of the complex of plasminogen activator inhibitor type 1 with tissue-type plasminogen activator by mass spectrometry and size-exclusion chromatography. Biochim Biophys Acta. 1996;1295(1):103-109.
26. de Fouw NJ, van Tilburg NH, Haverkate F, Bertina RM. Activated protein C accelerates clot lysis by virtue of its anticoagulant activity. Blood Coagul Fibrinolysis. 1993;4(2):201-210.
27. Bertina RM, van Tilburg NH, de Fouw NJ, Haverkate F. Thrombin, a link between coagulation activation and fibrinolysis. Ann N Y Acad Sci. 1992; 667:239-248.
28. de Fouw NJ, de Jong YF, Haverkate F, Bertina RM. Activated protein C increases fibrin clot lysis by neutralization of plasminogen activator inhibitorVno evidence for a cofactor role of protein S. Thromb Haemost. 1988;60(2):328-333.
29. de Fouw NJ, van Hinsbergh VW, de Jong YF, Haverkate F, Bertina RM. The interaction of activated protein C and thrombin with the plasminogen activator inhibitor released from human endothelial cells. Thromb Haemost. 1987;57(2):176-182.
30. Brohi K, Cohen MJ, Ganter MT, Matthay MA, Mackersie RC, Pittet JF. Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway? Ann Surg. 2007;245(5):812-818.
31. Cohen MJ. Towards hemostatic resuscitation: the changing understanding of acute traumatic biology, massive bleeding, and damage-control resuscitation. Surg Clin North Am. 2012;92(4):877-891 viii.
32. Schöchl H, Frietsch T, PavelkaM, Jámbor C. Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma. 2009;67(1):125-131.
33. Hess JR, Brohi K, Dutton RP, Hauser CJ, Holcomb JB, Kluger Y, Mackway-Jones K, Parr MJ, Rizoli SB, Yukioka T, et al. The coagulopathy of trauma: a review of mechanisms. J Trauma. 2008;65(4):748-754.
34. Kashuk JL, Moore EE, Sawyer M,Wohlauer M, Pezold M, Barnett C, Biffl WL, Burlew CC, Johnson JL, Sauaia A. Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma. Ann Surg. 2010; 252(3):434-442.
35. Kutcher ME, Ferguson AR, Cohen MJ. A principal component analysis of coagulation after trauma. J Trauma Acute Care Surg. 2013;74(5): 1223-1229.
36. Nordenhem A, Leander K, Hallqvist J, de Faire U, Sten-Linder M, Wiman B. The complex between tPA and PAI-1: risk factor for myocardial infarction as studied in the SHEEP project. Thromb Res. 2005;116(3): 223-232.
37. Bounameaux H, Kruithof EK. On the association of elevated tPA/PAI-1 complex and von Willebrand factor with recurrent myocardial infarction. Arterioscler Thromb Vasc Biol. 2000;20(8):1857-1859.
38. Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR. High circulating adrenaline levels at admission predict increased mortality after trauma. J Trauma Acute Care Surg. 2012;72(2):428-436.
39. Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg. 2011;254(2):194-200.
40. Hrafnkelsdottir T, Gudnason T,Wall U, Jern C, Jern S. Regulation of local availability of active tissue-type plasminogen activator in vivo in man. J Thromb Haemost. 2004;2(11):1960-1968.
41. Hrafnkelsdóttir T, Ottosson P, Gudnason T, Samuelsson O, Jern S. Impaired endothelial release of tissue-type plasminogen activator in patients with chronic kidney disease and hypertension. Hypertension. 2004;44(3): 300-304.
42. Burggraaf J, Schoemaker HC, Kroon JM, Huisman L, Kluft C, Cohen AF. Influence of 1-desamino-8-D-vasopressin on endogenous fibrinolysis, haemodynamics and liver blood flow in healthy subjects. Clin Sci (Lond). 1994;86(5):497-503.
43. Raza I, Davenport R, Rourke C, Platton S, Manson J, Spoors C, Khan S, De'Ath HD, Allard S, Hart DP, et al. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost. 2013;11(2): 307-314.
44. Cardenas JC, Matijevic N, Baer LA, Holcomb JB, Cotton BA, Wade CE. Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients. Shock. 2014;41(6): 514-521.
45. Bontekoe IJ, van der Meer PF, de Korte D. Determination of thromboelastographic responsiveness in stored single-donor platelet concentrates. Transfusion. 2014;54(6):1610-1618.
46. Katori N, Tanaka KA, Szlam F, Levy JH. The effects of platelet count on clot retraction and tissue plasminogen activatorYinduced fibrinolysis on thrombelastography. Anesth Analg. 2005;100(6):1781-1785.
47. Hosomi N, Lucero J, Heo JH, Koziol JA, Copeland BR, del Zoppo GJ. Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion. Stroke. 2001;32(6):1341-1348.
48. MacLeod JB, Winkler AM, McCoy CC, Hillyer CD, Shaz BH. Early trauma induced coagulopathy (ETIC): prevalence across the injury spectrum. Injury. 2014;45(5):910-915.
49. Shaz BH, Winkler AM, James AB, Hillyer CD, MacLeod JB. Pathophysiology of early trauma-induced coagulopathy: emerging evidence for hemodilution and coagulation factor depletion. J Trauma. 2011;70(6): 1401-1407.
50. Schöchl H, Maegele M, Solomon C, Görlinger K, Voelckel W. Early and individualized goal-directed therapy for trauma-induced coagulopathy. Scand J Trauma Resusc Emerg Med. 2012;20:15.
51. Moore HB, Moore EE, Gonzalez E, Chapman MP, Chin TL, Silliman CC, Banerjee A, Sauaia A. Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy. J Trauma Acute Care Surg. 2014;77(6): 811-817.
52. Cao Y, Dua A, Matijevic N,WangYW, Pati S,Wade CE, Ko TC, Holcomb JB. Never-frozen liquid plasma blocks endothelial permeability as effectively as thawed fresh frozen plasma. J Trauma Acute Care Surg. 2014; 77(1):28-33.
53. Johansson PI, Sørensen AM, Perner A, Welling KL, Wanscher M, Larsen CF, Ostrowski SR. Disseminated intravascular coagulation or acute coagulopathy of trauma shock early after trauma? An observational study. Crit Care. 2011;15(6):R272.